UMIN-CTR Clinical Trial
| Unique ID issued by UMIN | UMIN000016879 |
|---|---|
| Receipt number | R000019596 |
| Scientific Title | Mutation analyses of plasma and tumor DNA in EGFR mutation-positive advanced non-small-cell lung cancer. |
| Date of disclosure of the study information | 2015/03/23 |
| Last modified on | 2018/09/25 16:20:32 |
* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments
Basic information
Public title
Mutation analyses of plasma and tumor DNA in EGFR mutation-positive advanced non-small-cell lung cancer.
Acronym
Liquid Biopsy Study
Scientific Title
Mutation analyses of plasma and tumor DNA in EGFR mutation-positive advanced non-small-cell lung cancer.
Scientific Title:Acronym
Liquid Biopsy Study
Region
| Japan |
Condition
Condition
non-small-cell lung cancer
Classification by specialty
| Pneumology | Laboratory medicine |
Classification by malignancy
Malignancy
Genomic information
YES
Objectives
Narrative objectives1
To investigate clinical benefit of liquid biopsy by measuring a somatic cell mutation such as EGFR gene mutation from peripheral circulating free DNA (tumor-specific circulating cell-free DNA: cfDNA) derived from plasma and DNA derived from tumors collected before and after treatment with EGFR-tyrosine kinase inhibitor (EGFR-TKI) using digital PCR and next-generation sequencer in patients with EGFR gene mutation-positive non-small-cell lung cancer.
Basic objectives2
Others
Basic objectives -Others
Clinical benefit of liquid biopsy by measuring the somatic cell mutation such as EGFR gene mutation.
Trial characteristics_1
Trial characteristics_2
Developmental phase
Assessment
Primary outcomes
Detection of EGFR gene mutation from cfDNA collected before and after treatment with EGFR-TKI in patients with EGFR gene mutation- positive non-small-cell lung cancer.
Key secondary outcomes
Detection of a biomarker about EGFR-TKI tolerance.
Coincidence ratio of detection of EGFR gene mutation between tissue samples and cfDNA.
Association between the clinical background including a presence or absence of T790M gene mutation and the prognosis.
Base
Study type
Observational
Study design
Basic design
Randomization
Randomization unit
Blinding
Control
Stratification
Dynamic allocation
Institution consideration
Blocking
Concealment
Intervention
No. of arms
Purpose of intervention
Type of intervention
Interventions/Control_1
Interventions/Control_2
Interventions/Control_3
Interventions/Control_4
Interventions/Control_5
Interventions/Control_6
Interventions/Control_7
Interventions/Control_8
Interventions/Control_9
Interventions/Control_10
Eligibility
Age-lower limit
| 20 | years-old | <= |
Age-upper limit
| Not applicable |
Gender
Male and Female
Key inclusion criteria
1)Patients with EGFR gene mutation (exon 19 deletion, L858R, G719X, L861M, T790M, etc) -positive non-small-cell lung cancer determined with a histological diagnosis or cytodiagnosis.
2)Patients with treatment plan of EGFR-TKI alone or combination therapy including EGFR-TKI. In addition, plasma samples of patients before treatment are stored at -80 degrees Celsius even if after the start of treatment.
3)Patients with more than 20 years.
4)Patients providing written informed consent.
Key exclusion criteria
1) Patient with positive HBs antigen or HVC antibody.
2) Patient with definite positive HIV antibody (need not for examination).
3) Any other patients who are regarded as unsuitable for this study by the investigators.
Target sample size
100
Research contact person
Name of lead principal investigator
| 1st name | |
| Middle name | |
| Last name | Isamu Okamoto |
Organization
Kyushu University Hospital
Division name
Research Institute for Disease of the Chest / Center for Clinical and Translational Research
Zip code
Address
3-1-1 Maidashi, Higashi-ku, Fukuoka-city, Fukuoka 812-8582, Japan
TEL
092-642-5378
okamotoi@kokyu.med.kyushu-u.ac.jp
Public contact
Name of contact person
| 1st name | |
| Middle name | |
| Last name | Noriko Hidaka |
Organization
Graduate School of Medical Sciences, Kyushu University
Division name
Research Institute for Disease of the Chest
Zip code
Address
3-1-1 Maidashi, Higashi-ku, Fukuoka-city, Fukuoka 812-8582, Japan
TEL
092-642-5378
Homepage URL
noriko-f@kokyu.med.kyushu-u.ac.jp
Sponsor or person
Institute
Clinical Research Support Center Kyushu
Institute
Department
Personal name
Funding Source
Organization
Ministry of Health, Labour and Welfare.
Organization
Division
Category of Funding Organization
Japanese Governmental office
Nationality of Funding Organization
Japan
Other related organizations
Co-sponsor
Name of secondary funder(s)
IRB Contact (For public release)
Organization
Address
Tel
Secondary IDs
Secondary IDs
NO
Study ID_1
Org. issuing International ID_1
Study ID_2
Org. issuing International ID_2
IND to MHLW
Institutions
Institutions
Other administrative information
Date of disclosure of the study information
| 2015 | Year | 03 | Month | 23 | Day |
Related information
URL releasing protocol
Publication of results
Unpublished
Result
URL related to results and publications
Number of participants that the trial has enrolled
Results
Results date posted
Results Delayed
Results Delay Reason
Date of the first journal publication of results
Baseline Characteristics
Participant flow
Adverse events
Outcome measures
Plan to share IPD
IPD sharing Plan description
Progress
Recruitment status
Completed
Date of protocol fixation
| 2015 | Year | 02 | Month | 09 | Day |
Date of IRB
Anticipated trial start date
| 2015 | Year | 02 | Month | 18 | Day |
Last follow-up date
| 2017 | Year | 12 | Month | 31 | Day |
Date of closure to data entry
Date trial data considered complete
| 2018 | Year | 09 | Month | 18 | Day |
Date analysis concluded
Other
Other related information
Peripheral blood (7ml, EDTA-2Na) is collected before treatment with EGFR-TKI (from -4 weeks to treatment start day) and at 12 weeks, at 24weeks, at 36 weeks, after every 12 weeks (the allowance day: 1 week) after treatment start and at disease progression (within 2 weeks after PD confirmation).
The submission of tumor samples is not essential.
However, the following samples are submitted to investigate the correlation between tumor sample and cfDNA about having T790M gene mutation or not, in the cases that one of the following samples (no limit at collection time) are stored before start of EGFR-TKI treatment, or a re-biopsy is carried out from the progression of disease during treatment with EGFR-TKI.
/Six pieces of slide specimens which performed slicing to a 4-5 microns thickness of the paraffin embedded specimen.
/One piece of prepared slide (Papanicolaou stain) used for a cytodiagnosis.
/Twenty ml (10mLx2) of malignant pleural effusion was centrifuged (1400g for 10min at room temperature), and stored two pellets at -80 degrees Celsius after removal of a supernatant. The supernatant is not removed too much (leave around 1cm).
/DNA extract (samples after EGFR gene mutation examination)
/Cell block
Management information
Registered date
| 2015 | Year | 03 | Month | 23 | Day |
Last modified on
| 2018 | Year | 09 | Month | 25 | Day |
Link to view the page
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000019596
